{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:10:10Z","timestamp":1791382210613,"version":"4.3.3"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T00:00:00Z","timestamp":1340150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0039412","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T12:09:34Z","timestamp":1340280574000},"page":"e39412","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Investigation of the In Vitro Therapeutic Efficacy of Nilotinib in Immortalized Human NF2-Null Vestibular Schwannoma Cells"],"prefix":"10.1371","volume":"7","author":[{"given":"Nesrin","family":"Sabha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolyn","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Agnihotri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupinder","family":"Mangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1215\/15228517-2007-027","article-title":"Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature.","volume":"9","author":"A Balasubramaniam","year":"2007","journal-title":"Neuro-Oncology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/FOC\/2008\/24\/5\/E2","article-title":"Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors.","volume":"24","author":"WD Johnson","year":"2008","journal-title":"Neurosurg Focus"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1749-4486.2008.01715.x","article-title":"Conservative versus primary surgical treatment of acoustic neuromas: a comparison of rates of facial nerve and hearing preservation.","volume":"33","author":"TPC Martin","year":"2008","journal-title":"Clin Otolaryngology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate neurofibromatosis 2 tumor suppressor.","volume":"72","author":"JA Trofatter","year":"1993","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.","volume":"363","author":"GA Rouleau","year":"1993","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nrm882","article-title":"ERM proteins and merlin: integrators at the cell cortex.","volume":"3","author":"A Bretscher","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","article-title":"Conditional biallelic <italic>Nf2<\/italic> mutation in the mouse promotes manifestations of human neurofibromatosis type 2.","volume":"14","author":"M Giovannini","year":"2000","journal-title":"Genes Dev"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"18200","DOI":"10.1073\/pnas.0405971102","article-title":"Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L.","volume":"101","author":"R Rong","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/0008-5472.CAN-07-5849","article-title":"Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.","volume":"68","author":"S Ammoun","year":"2008","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1158\/0008-5472.CAN-08-4475","article-title":"Human schwannomas express activated platelet-derived growth factor receptors and c-KIT and are growth inhibited by Gleevec (imatinib mesylate).","volume":"69","author":"J Mukherjee","year":"2009","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"BJ Druker","year":"2001","journal-title":"NEJM"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"BJ Druker","year":"2001","journal-title":"NEJM"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.","volume":"347","author":"JF Apperley","year":"2002","journal-title":"NEJM"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","volume":"347","author":"GD Demetri","year":"2002","journal-title":"NEJM"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL.","volume":"7","author":"E Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","article-title":"Extended kinase profile and properties of the protein kinase inhibitor Nilotinib.","volume":"1804","author":"PW Manley","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354","author":"H Kantarjian","year":"2006","journal-title":"NEJM"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.208","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.","volume":"87","author":"C Tanaka","year":"2010","journal-title":"Clinical Pharmacol Ther"},{"key":"ref19","first-page":"475","article-title":"Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol.","volume":"20(3)","author":"G Hung","year":"2002","journal-title":"Mar"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","article-title":"Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.","volume":"13(7)","author":"S Ammoun","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/Merlin is a novel negative regulator of mTOR Complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.","volume":"29","author":"MF James","year":"2009","journal-title":"Mol Cell Bio"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"37064","DOI":"10.1074\/jbc.M304968200","article-title":"Kinetic analysis of platelet-derived growth factor receptor\/phosphoinositide 3-kinase\/Akt signaling in fibroblasts.","volume":"278","author":"CS Park","year":"2003","journal-title":"J Biol Chem"},{"key":"ref23","first-page":"142","article-title":"Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutat Res.","volume":"637(1\u20132)","author":"P Lepont","year":"2008","journal-title":"1"},{"key":"ref24","first-page":"1493","article-title":"Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol.","volume":"23(6)","author":"JT Fraenzer","year":"2003"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0039412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T05:45:47Z","timestamp":1642571147000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0039412"}},"subtitle":[],"editor":[{"given":"Nikos K.","family":"Karamanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,6,20]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0039412","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,20]]}}}